Jurox Vetace Cardiovascular Treatment for Dogs Cat Tablets 2.5mg
Jurox Vetace Cardiovascular Treatment for Dogs Cat Tablets 2.5mg
This is a prescription medicine. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item. The original, physical copy of the accompanying prescription will be collected upon delivery.
VetACE contains benazepril hydrochloride which is an ACE (Angiotensin Converting Enzyme) inhibitor drug that helps to control vasoconstriction of both arteries and veins and retention of sodium and water by the kidney.
VETACE FOR DOGS:
Treatment of left-sided heart failure in dogs (e.g. Mitral Valve Regurgitation and Dilated Cardiomyopathy (DCM)
Inhibits the renin angiotensin aldosterone (RAA) system, minimising the undesirable effects of vasoconstriction and sodium retention
Generally will improve the clinical status of the patient
May be used in combination therapy with diuretics (for example frusemide), digoxin and antiarrhythmic drugs as necessary
VETACE FOR CATS:
Indicated for the treatment of chronic renal insufficiency in cats by reducing protein loss in urine and lowering systemic and intraglomerular blood pressure
Has some beneficial effects on clinical signs and cardiac remodelling in cats with feline hypertrophic cardiomyopathy (HCM) and is well tolerated
PRECAUTIONS:
DOGS AND CATS:
The safety of VetACE has not been tested in breeding dogs or cats. VetACE is therefore not recommended for use in pregnant or lactating animals
Clinical trials showed that VetACE was well tolerated in patients. A small number of animals may exhibit transient signs of fatigue
Clinical trials have shown no evidence of VetACE causing renal toxicity - routine monitoring is recommended in animals with kidney problems
Transient reversible hypotension may occur in cases of accidental overdosage.
Active Ingredient : Each tablet contains 2.5mg benazepril hydrochloride
Package Size: Dispensed according to prescription.